# Equity Strategy US ELECTION: JUST A TRADE, NOT A REGIME SHIFT

Assuming we get to the US presidential election with the US indices and valuations around current levels, we would tactically recommend a NEUTRAL stance expecting higher volatility around the event in case of higher chances of a Republican sweep. Strategically, we would remain OVERWEIGHT on the asset class throughout 2025 as recession risk remains negligible.

At the margin, we see Trump's victory as a trading opportunity rather than a radical shift in the paradigm that has driven US and global indices towards all-time highs. We still believe that the Growth/Quality sectors will strategically keep outperforming as long as the Fed remains in easing mode, the economy slows down without falling into recession, inflation keeps heading towards the target, and AI hype persists.

We acknowledge the possibility of quick and sharp rotations towards Value/Traditional Cyclicals and Small Caps, but our macro scenario does not support their sustainability over time in 2025. That said, we see a structural rotation from Growth/Quality to Value as detrimental for equities, as regime changes within the asset class are rarely painless, but we would take advantage of it.




Cosimo Recchia Senior Equity Strategist Investment Research

### **Demystifying the Trump Trade**

We disagree, at least from a strategic perspective, that former President Trump's victory would support the "Trump Trade". The odds of Trump's victory skyrocketed in the first weeks of July triggering a sharp rotation within the market that lost approximately 9% over the following three weeks. Both Small Caps and Value names outpaced their relative counterparties by 14pp, before giving back parts of the gains going through August (Figure 1). We saw similar dynamics back in 2016, when Small Caps and Value were outperforming while the S&P was rolling over as Trump experienced more and more favorable polls. Interestingly, back then the Trump Trade was short lived and exhausted itself within a month from the election (Figure 2). So, the chance of a Trump victory fueled the Trump Trade, but Trump's actual victory halted it – we expect something similar to happen this time around, too.

FIGURE 1.


The Trump Trade in summer 2024: Small Caps (LHS) and Value (RHS)





### FIGURE 2.

The Trump Trade in the 2016 US presidential election: Small Caps (LHS) and Value (RHS)




We also disagree with mainstream thinking that Trump's victory would trigger

a broadening of the market. The 2016 episode points out that such conviction is "fake news". In fact, the aftermath of Trump's first victory was the beginning of the unstoppable narrowing of the US bull market. In November 2016, the largest five companies in the S&P 500 accounted for approximately 12% of the total market cap, then their weight steadily increased over time up to 24% at the end of his mandate. Now they account for 28% of the index (Figure 3). We continue to see any eventual market broadening that may unfold following Trump's victory as short-lived, like that which materialized in 2022 with the post-Covid reopening and rising inflation.

FIGURE 3.

Cumulative weight of the largest 5 companies in the S&P 500



Source: S&P, BofA, ANIMA Research



### We are not in 2016

In this section we explore in more detail the reasons that make us skeptical on strategically chasing the Trump Trade. Back in 2016 the macro and companies' fundamentals might have supported the idea of a lasting outperformance of Small Caps and Value, but we do not see those conditions now.

Below we highlight the main differences between now and 2016. We have checked for the underlying macro, equity prices, corporate fundamentals, and analyst forecasts.

MACRO BACKDROP: in a nutshell, we are now in the late stage of the economic cycle rather than at the dawn of a synchronized worldwide GDP growth as was the case in October 2016. Geopolitical headwinds are stronger today than eight years ago, governments have less room for fiscal easing after the national debts skyrocketed during the pandemic.

**EQUITY PERFORMANCE AND VALUATIONS:** from a price standpoint the S&P 500 looks quite like it was back in October 2016. In both cases, the US benchmark hovers around the relative peak (**Figure 4**). However, the index looks different from a valuation perspective. The S&P 500 is indeed more expensive now than it was eight years ago on all the most common metrics. Interestingly, the judgment changes when comparing multiples against their own last five years of history. This analysis highlights how the **S&P 500 was actually relatively quite expensive even at that time**, especially on Trailing Price to Earnings, whereas it was cheap and fairly priced on Dividend Yield and Equity Risk Premium (ERP). Nowadays, despite trading 26 times the EPS, the index does not look so expensive compared to its history, while it does on Price to Book and ERP (**Figure 5**). The latter especially seems to be quite stretched at 0.6% (**Figure 6**), offering little protection from a severe, but unlikely according to us, treasuries sell-off.







FIGURE 6.


S&P 500 - Now against end of October 2016

		Now	October 2016
	S&P 500 Level	5635	2123
Performance	From Previous Peak	-1%	-3%
	12M Forward Performance	na	21%
	Tralling PE	26	23
	12M Forward PE	21	17
Valutation	Price to Book	5	3
valutation	Price to Cash	19	13
	Dividend Yield	1%	2%
	Equity Risk Premium (ERP)	1%	4%
	Trailing PE	0	2
	12M Forward PE	1	1
Valutation vs the last	Price to Book	2	1
5 years (z-score)	Price to Cash	1	1
	Dividend Yield	1	-1
	Equity Risk Premium (ERP)	2	0
	Return on Equity	19%	12%
	EPS From Previous Peak	0%	-13%
Fundamentals	12M Trailing EPS Growth	11%	-8%
i unuamentais	12M Forward EPS Growth	14%	3%
	Net Margin	12%	10%
	Net Debt to EBITDA	2	2

Source: S&P, MSCI, ANIMA Research

**TRAILING EARNINGS:** From a profitability and fundamentals standpoint, US listed companies look in different shape. Corporate America now seems to be in a maturing cycle with earnings, margins, and Return on Equity at or still around their all-time highs. Back in 2016, US EPS was already contracting by 13pp compared to the previous peak recorded in March 2015 (**Figure 7**). At that time, 10 out of 24 sectors, especially commodities-related ones, were experiencing an earnings slowdown (APPENDIX). Consequently, even margin and RoE were in downward trajectories (**Figure 8** and **Figure 9**) whilst leverage was rising fast (**Figure 10**).





**EARNINGS EXPECATIONS**: This time around EPS growth expectations look to be more constructive than 2016. That October consensus analysts were forecasting US EPS to increase by a paltry 3% over the following next 12 months, whilst now they foresee a cheerful 14% expansion. History points out that eight years ago analysts were too conservative, in fact 12 months later, US EPS grew by 15%, led by Energy, Diversified Financials and IT sectors (Figure 11). Our current macro scenario suggests that nowadays analysts may be too optimistic in their double-digit forecasts. Historically, 1pp quarterly GDP growth has translated to 4.5pp in EPS growth (excl. Fins), all else equal, since 1948. For H1 2025, on average, we expect growth at 1.9% q/q SAAR and 1.7% for H2 2025 - consistent with an annual growth rate of 2.1%. This would imply EPS growth in the high single digits next year.

6/13

FIGURE 11.

US sector EPS growth estimates now against October 2016

		Expected Forward EPS Growth		EPS Growth - Actual Data		
		Now	October 2016	1yr Later - October 2017		
	USA	14	3	15		
	Cons. Services	19	12	10		
	Cons. Durables	5	9	6		
	Comm. & Prof. Svcs	10	6	6		
	Capital Goods	11	2	4		
als	Div. Financials	13	2	30		
Cyclicals	Insurance	21	2	4		
کّ	Materials	-1	-1	25		
	Real Estate	5	-1	-8		
	Banks	8	-3	13		
	Transportation	1	-4	-9		
	Energy	0	-17	190		
	Semis	74	31	30		
	Software	17	11	30		
Growth	Retailing	45	9	9		
Sro	Media & Ent.	35	6	8		
	Tech	12	-2	1		
	Auto	2	-4	-12		
	Pharma	О	10	3		
	Health Care	8	9	14		
ves	Food, Bev, Tobacco	2	6	4		
Defensives	Food & Staples Ret.	3	6	5		
)ef	Telecoms	4	4	5		
	HH & Personal Products	9	3	19		
	Utilities	9	0	33		

Source: MSCI, ANIMA Research

# Our macro baseline suggests Quality/Growth over Traditional Cyclicals

Below we introduce the implications for US equity under both scenarios: Split Congress (**Scenario 1**) and a Republican sweep (**Scenario 2**). We have checked for economic growth, inflation, and monetary policy.

**GROWTH:** we do not expect much in 2025, beyond then will depend on the Congress outcome. In our view, the new Trump presidency will not provide any relevant impulse to the economic growth in 2025.


▶ **Scenario 1:** under a split Congress, we see no growth impulse in 2025, but downside risks mounting for 2026. Failure to extend in full the TCJA beyond 2025 will result in a slightly negative growth impact. This will weigh on equity prices and especially on high beta sectors, like traditional cyclical ones.



▶ **Scenario 2:** under a Republican sweep, we do not see further corporate tax cuts as likely. If anything, Trump will manage to cut by just 1% bringing the tax rate down to 20%. Last time he slashed it to 21% from the previous 35%. So, at the margin, the new, still unlikely, fiscal easing for corporates is not as favorable as during the first term. The extensions of the TCJA kicking in from the end 2025 would reduce downside risks embedded in Scenario 1. However, it would have only an incrementally negligible effect on personal consumption, being more of a maintenance of the status quo rather than an extra impulse to economic growth. For these reasons, we consider it to be unfounded to switch fully into traditional cyclical sectors (i.e. Energy, Materials, Industrials, Financials, Consumer Durables, and Consumer Services) going through 2025. In fact, a lasting reacceleration of the economic activity, proxied by rising ISM, is crucial to trigger a sustainable outperformance of Cyclicals over Defensives (Figure 12). When we check for the main macro variables, we see that none supports a cyclical rebound (Figure 13). We expect commodities prices not to rise from current levels, we do not expect Industrial Production and Retail Sales to pick up from here, and consequently ISMs should keep hovering around the current prints.

### FIGURE 12.

Traditional Cyclicals against Defensives and ISMs




Source: MSCI, ANIMA Research. Traditional Cyclicals: Energy, Materials, Industrials, Financials, Consumer Durables, Consumer Services. Defensives: Telecoms, Utilities, Health Care, Consumer Staples.



### FIGURE 13.

Traditional Cyclicals against Defensives and main economic variables




Source: MSCI, Datastream, ANIMA Research. Traditional Cyclicals: Energy, Materials, Industrials, Financials, Consumer Durables, Consumer Services. Defensives: Telecoms, Utilities, Health Care, Consumer Staples.

**INFLATION:** we expect no impulse in 2025, little through goods in 2026 and beyond. Such a view supports a sector allocation tilted toward a balanced mix of Quality/Growth and Defensives. Historically, and especially pre-Covid, the relative performance of Traditional Cyclicals is positively correlated with the Inflation Breakeven (**Figure 14**). Assuming it remains near the current 2% and considering our economic growth outlook, we do not anticipate Traditional Cyclicals to outperform.

### FIGURE 14.

US Cyclicals relative to Defensives and US Breakeven




Source: MSCI, Datastream, ANIMA Research. Traditional Cyclicals: Energy, Materials, Industrials, Financials, Consumer Durables, Consumer Services. Defensives: Telecoms, Utilities, Health Care, Consumer Staples.

That said, we prefer to take exposure to cyclicality from Quality/Growth sectors, which are more agnostic to Breakeven movements (Figure 12).



### FIGURE 15.

Correlations: US sector performances and US Breakeven – From Jan 2014 to Jun 2020



Source: MSCI, Datastream, ANIMA Research. Note: Tesla is not included in this analysis, as it was included in the US equity benchmark only in December 2020.

MONETARY POLICY: we see no impulse in 2025, little if any in 2026. Over the past three decades, barring a recession, an accommodative Federal Reserve has been favorable for the S&P 500. In terms of market sectors, except for the 2001 Tech Bubble, Growth stocks consistently outperformed Value stocks, whether or not a recession occurred (refer to Figure 16 and Figure 17).

### FIGURE 16.

S&P 500 and Growth relative to Value over the last 30 years




FIGURE 17.

S&P 500 and Growth relative to Value during the Fed's last 5 cuts

			Forward Performance (%)					
	First Cut Dates	Recession	1 week	1 month	3 months	6 months	9 months	12 months
	Jul - 1995	No	2	2	6	13	20	20
	Sep - 1998	No	-6	2	17	22	27	22
S&P	Jan - 2001	Mar 2001 - Nov 2001	1	5	-11	-4	-18	-10
500	Aug - 2007	Dec 2007 - Jun 2009	4	5	3	-4	1	-8
	Jul - 2019	Mar 2020 - Apr 2020	-4	-3	1	9	-3	8
	P	Average	-1	2	3	7	5	6
	Н	lit Ratio	60	80	80	60	60	60

			Forward Performance (%)						
	First Cut Dates	Recession	1 week	1 month	3 months	6 months	9 months	12 months	
	Jul - 1995	No	0	0	1	-2	0	4	
	Sep - 1998	No	-5	0	8	12	4	16	
Growth Relative	Jan - 2001	Mar 2001 - Nov 2001	5	8	-14	-9	-17	-10	
to Value	Aug - 2007	Dec 2007 - Jun 2009	0	2	8	6	10	14	
	Jul - 2019	Mar 2020 - Apr 2020	0	2	0	7	24	38	
	P	Average	0	2	1	2	-1	6	
	Н	lit Ratio	80	80	80	60	60	80	

Source: S&P, Russell, Datastream, ANIMA Research

### Tariffs and global sector exposure to the US

Non-US listed companies generate 14% of sales in the US (**Figure 18**). The largest and most exposed sectors are Pharma (34%), Software (30%), Semiconductors (22%), Auto (25%), and Tech (21%). Sectors towards the bottom of the ranking such as Retail, Utilities, Banks and Real Estate are more locally driven so they should be less affected.

Geographically, listed companies that generate a significant portion of their revenue from the US are predominantly located in Europe. Switzerland and the UK stand out due to the heavy weights of Pharmaceuticals and Health Care, garnering over one-fourth of their sales from the US market. Companies in the EMU see slightly less exposure at under 20%. In Emerging Markets, Asian businesses have the smallest overall dependency on US sales; however, those in IT-related industries are still notably vulnerable.

FIGURE 18.

Stock Market Sales Exposure to North America – Sector and Region

	Global ex North America	Switzerland	UK	EMU	Japan	LATAM	CEEMEA	EM ASIA
Pharma, Biotech & Life Sciences	34%	42%	47%	37%	35%		27%	10%
Commercial & Professional Services	32%	14%	46%	31%	14%			
Software % Services	30%	17%	45%	33%	7%			
Cons. Staples Distribution & Retail	30%			25%	40%	2%		
Automobilies & Components	25%			26%	37%			13%
Consumer Services	23%		57%	17%				2%
Semiconductors	22%			12%	11%			25%
Technology Hardware & Equipment	21%	35%	42%	31%	15%			21%
Household & Personal Products	20%		31%	22%	3%	2%		3%
Health Care Equipment & Services	19%	41%	52%	44%	23%			0%
Consumer Durables & Apparel	17%	20%	5%	23%	21%			7%
Food Beverage & Tobacco	14%	31%	25%	18%	9%	30%		2%
Telecommunication Services	14%			35%				0%
Energy	13%		38%	9%	3%	3%	10%	1%
Materials	12%	32%	24%	21%	9%	16%	5%	3%
Insurance	12%	29%	6%	10%	8%			
Capital Goods	12%	25%	40%	23%	16%	18%		2%
Media & Entertainment	11%		39%	31%	13%		10%	1%
Financial Services	11%	1%	9%	10%	2%			
Transportation	9%	28%		5%	2%	5%	7%	4%
Equity REITs	8%			10%				
Banks	7%		9%	4%	7%	1%	0%	0%
Utilities	4%		19%	4%				
Cons. Discr. Distribution & Retail	4%	8%	11%	0%	3%			0%
Real Estate Management & Dev.	2%				3%			0%
Grand Total	14%	27%	26%	18%	16%	9%	6%	5%

Source: Citi, Factset, ANIMA Research

### **APPENDIX**

### FIGURE 1A.

Trailing EPS growth

		12M Trailing EPS Growth				
		Now	October 2016			
	USA	11	-8			
	Cons Services	104	22			
	Cons. Durables	10	13			
	Transportation	-9	12			
	Banks	1	7			
als.	Capital Goods	7	2			
Cyclicals	Real Estate	4	2			
S	Comm. & Prof. Svcs	18	-4			
	Div. Financials	61	-9			
	Insurance	50	-22			
	Materials	-24	-27			
	Energy	-38	-125			
	Auto	11	42			
	Media & Ent.	56	9			
Growth	Retailing	69	7			
5	Tech	8	2			
	Semis	56	-2			
	Software	33	-7			
	Telecoms	2	65			
	Pharma	-25	17			
ves	Health Care	14	5			
Defensives	Food, Bev. & Tobacco	17	4			
Def	HH & Personal Product	8	-9			
	Food & Staples Ret.	30	-10			
	Utilities	19	-22			

Source: MSCI, Datastream, ANIMA Research

### Marketing material for professional clients or qualified investors only.

This material does not constitute an advice, an offer to sell, a solicitation of an offer to buy, or a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.

ANIMA can in no way be held responsible for any decision or investment made based on information contained in this document. The data and information contained in this document are deemed reliable, but ANIMA assumes no liability for their accuracy and completeness.

ANIMA accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material in violation of this disclaimer and the relevant provisions of the Supervisory Authorities.

### This is a marketing communication.

Please refer to the Prospectus, the KID, the Application Form and the Governing Rules ("Regolamento di Gestione") before making any final investment decisions. These documents, which also describe the investor rights, can be obtained at any time free of charge on ANIMA website (<a href="https://www.animasgr.it">www.animasgr.it</a>). Hard copies of these documents can also be obtained from ANIMA upon request. The KIDs are available in the local official language of the country of distribution. The Prospectus is available in Italian/English. Past performances are not an indicator of future returns. The distribution of the product is subject to the assessment or suitability or adequacy required by current regulations. ANIMA reserves the right to amend the provided information at any time. The value of the investment and the resulting return may increase or decrease and, upon redemption, the investor may receive an amount lower than the one originally invested.

In case of collective investment undertakings distributed cross-border, ANIMA is entitled to terminate the provisions set for their marketing pursuant to Article 93 Bis of Directive 2009/65/EC.

